Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Raven biotechnologies has entered into a research collaboration with Leland Chung, director of the Molecular Urology and Therapeutics Program at the Emory University Medical School's Department of Urology.
Subscribe to our email newsletter
Under the terms of the collaboration, Raven will provide Emory with access to its prostate cancer stem cells. Raven will also provide Emory with a library of antibodies targeting cancer stem cells to study their use as potential diagnostic tools for cancer prognosis and treatment. Using Raven’s unique prostate cancer derived cancer stem cells (CSCs), Raven and Emory will collaboratively examine prostate cancer biology, disease progression and subsequent metastasis.
George Schreiner, CEO of Raven biotechnologies, said: “We are excited about our collaboration with Emory University because of their work in cancer stem cells that compliments Raven’s expertise in this area, as well as their multidisciplinary approach to cancer research and clinical applications.”